Holen Sie sich die Stockscreener-App
28.83
1.16%
0.2869
Schlusskurs vom Vortag:
$28.54
Offen:
$28.1168
24-Stunden-Volumen:
541.26K
Relative Volume:
0.65
Marktkapitalisierung:
$1.66B
Einnahmen:
$825.94M
Nettoeinkommen (Verlust:
$185.68M
KGV:
9.0782
EPS:
3.1754
Netto-Cashflow:
$296.89M
1W Leistung:
+7.44%
1M Leistung:
-23.71%
6M Leistung:
-22.18%
1J Leistung:
-14.71%
1-Tages-Spanne:
$27.66
$28.95
1-Wochen-Bereich:
$25.90
$29.36
52-Wochen-Spanne:
$25.52
$40.87
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Firmenname
Harmony Biosciences Holdings Inc
Sektor
Branche
Telefon
(484) 539-9800
Adresse
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HRMY
Harmony Biosciences Holdings Inc
|
28.84 | 1.64B | 825.94M | 185.68M | 296.89M | 3.1754 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.73 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.45 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
764.24 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
331.21 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
313.29 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-11 | Fortgesetzt | UBS | Neutral |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Fortgesetzt | Goldman | Neutral |
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-12-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-10 | Eingeleitet | UBS | Buy |
| 2024-06-21 | Eingeleitet | Citigroup | Buy |
| 2024-01-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-09-25 | Herabstufung | Goldman | Neutral → Sell |
| 2023-09-07 | Eingeleitet | Berenberg | Buy |
| 2023-04-20 | Eingeleitet | BofA Securities | Neutral |
| 2022-10-14 | Hochstufung | Janney | Neutral → Buy |
| 2022-10-14 | Hochstufung | Jefferies | Hold → Buy |
| 2022-08-03 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-13 | Herabstufung | Goldman | Buy → Neutral |
| 2022-07-07 | Eingeleitet | Mizuho | Buy |
| 2022-04-14 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2021-12-01 | Eingeleitet | Oppenheimer | Outperform |
| 2021-11-04 | Eingeleitet | Raymond James | Outperform |
| 2021-09-23 | Eingeleitet | Needham | Buy |
| 2021-03-29 | Hochstufung | Goldman | Neutral → Buy |
| 2020-09-14 | Eingeleitet | Goldman | Neutral |
| 2020-09-14 | Eingeleitet | Jefferies | Buy |
| 2020-09-14 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Harmony Biosciences Holdings Inc Aktie (HRMY) Neueste Nachrichten
US applications for jobless aid rose modestly to 212,000 last week as layoffs remain at historically healthy levels - Bitget
Safe Bulkers, Inc. to Participate in the Dry Bulk Shipping Panel at the DNB Carnegie Energy & Shipping Conference in Oslo - Bitget
Truist Securities Downgrades Harmony Biosciences Holdings, Inc. (HRMY) to Hold After Patent Trial Developments - Yahoo! Finance Canada
Harmony Biosciences (HRMY) Is Down 20.1% After Reaffirming WAKIX Outlook and Winning Pediatric Approval - simplywall.st
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
UBS Group Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $36.00 - MarketBeat
Harmony Biosciences (HRMY): UBS Lowers Price Target to $36 | HRM - GuruFocus
HC Wainwright Reiterates Buy Rating for HRMY with $55 Target | H - GuruFocus
Harmony Biosciences' (HRMY) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
BEAM's Q4 Loss Narrower Than Expected, Revenues Rise Y/Y - Finviz
RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up - Finviz
Repligen's Q4 Earnings Beat Estimates, Revenues Surge Y/Y - Finviz
Corcept's Q4 Earnings and Revenues Fall Short of Estimates - Finviz
Analysts Offer Insights on Healthcare Companies: ProQR (PRQR), Immunic (IMUX) and Harmony Biosciences Holdings (HRMY) - The Globe and Mail
UBS cuts Harmony Biosciences stock price target on earlier Wakix generic entry - Investing.com
Harmony Biosciences Holdings, Inc. Experiences Revision in Its Stock Evaluation Amid Market Volatility - Markets Mojo
Bank of America Lowers Harmony Biosciences (NASDAQ:HRMY) Price Target to $28.00 - MarketBeat
Needham & Company LLC Issues Pessimistic Forecast for Harmony Biosciences (NASDAQ:HRMY) Stock Price - MarketBeat
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Q4 2025 Earnings Call Transcript - Insider Monkey
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $36 at UBS - StreetInsider
CAVA Group To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
B of A Securities Lowers Harmony Biosciences (HRMY) Price Target to $28 | HRMY Stock News - GuruFocus
Decoding Harmony Biosciences Holdings Inc (HRMY): A Strategic SWOT Insight - GuruFocus
Harmony Biosciences Holdings, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Harmony Biosciences Holdings Inc (HRMY) Q4 2025 Earnings Call Hi - GuruFocus
Harmony Biosciences (HRMY) Reports Strong Q4 2025 Results, Eyes Blockbuster Revenue - GuruFocus
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $28 at BofA Securities - StreetInsider
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target By Investing.com - Investing.com Canada
Truist reiterates Hold on Harmony Biosciences stock, sets $25 target - Investing.com UK
Truist SecuritiesReinstates $25 target on Harmony Biosciences Holdings Inc. (HRMY) - StreetInsider
Harmony Biosciences Holdings (HRMY) Stock Analysis: Positioned for a 70% Upside in Biotech Sector - DirectorsTalk Interviews
Harmony Biosciences Hits Day Low at $26.03 Amid Price Pressure - Markets Mojo
Harmony Biosciences Holdings, Inc. Experiences Revision in Stock Evaluation Amid Market Volatility - Markets Mojo
Harmony Biosciences Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Harmony Bio misses Q4 2025 EPS estimates - Investing.com UK
Earnings call transcript: Harmony Bio misses Q4 2025 EPS estimates By Investing.com - Investing.com India
Zacks.com highlights 4 value stocks amid AI-driven market volatility - National Today
HRMY: Record revenue, strong WAKIX growth, and pipeline advances set up blockbuster 2026 - TradingView
Harmony Biosciences Holdings, Inc Reveals Retreat In Q4 Profit - Nasdaq
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates - Yahoo Finance
Harmony Biosciences Q4 Adjusted Net Income Drops, Net Product Revenue Rises; Full-Year 2026 Wakix Revenue Guidance Reiterated - marketscreener.com
Harmony Biosciences Reports $868.5 Million Revenue for 2025, Guidance for 2026 Exceeds $1 Billion - Intellectia AI
Harmony Biosciences Holdings, Inc. SEC 10-K Report - TradingView
Harmony Biosciences misses Q4 earnings despite revenue beat By Investing.com - Investing.com India
Harmony Biosciences misses Q4 earnings despite revenue beat - Investing.com
Earnings Flash (HRMY) Harmony Biosciences Holdings, Inc. Reports Q4 Revenue $243.8M, vs. FactSet Est of $240.3M - marketscreener.com
Harmony Biosciences Hldgs Earnings Review: Q4 Summary - Benzinga
Narcolepsy drug WAKIX nears $1B blockbuster year for Harmony Biosciences - Stock Titan
How The Story On Harmony Biosciences (HRMY) Is Shifting With Wakix Legal And Generic Risks - Yahoo Finance
Harmony Biosciences Shares Fall After Deutsche Bank Downgrade - marketscreener.com
Harmony Biosciences (HRMY) Faces Downgrades Amid Legal Concerns - GuruFocus
Finanzdaten der Harmony Biosciences Holdings Inc-Aktie (HRMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.68%
1.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):